RTW Biotech Opportunities (LSE:RTW) Total Assets: $1,069.0 Mil (As of Dec. 2025)


LSE:RTW RTW Biotech Opportunities Ltd LSE:RTW
36 GF Score
Price $2.43
! 2 Warning Signs
View Full Analysis

What is RTW Biotech Opportunities Total Assets?

RTW Biotech Opportunities LSE:RTW -1.62% 36 Total Assets is $1,069.0 Mil as of Dec. 2025. GuruFocus rates LSE:RTW with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

RTW Biotech Opportunities's Total Assets for the quarter that ended in Dec. 2025 was $1,069.0 Mil.

During the past 12 months, RTW Biotech Opportunities's average Total Assets Growth Rate was 40.90% per year. During the past 3 years, the average Total Assets Growth Rate was 39.10% per year. During the past 5 years, the average Total Assets Growth Rate was 20.30% per year.

During the past 8 years, RTW Biotech Opportunities's highest 3-Year average Total Assets Growth Rate was 87.40%. The lowest was 2.10%. And the median was 24.40%.

Total Assets is connected with ROA %. RTW Biotech Opportunities's annualized ROA % for the quarter that ended in Dec. 2025 was 62.32%. Total Assets is also linked to Revenue through Asset Turnover. RTW Biotech Opportunities's Asset Turnover for the quarter that ended in Dec. 2025 was 0.31.

RTW Biotech Opportunities  (LSE:RTW) Total Assets Explanation

Total Assets is connected with ROA %.

RTW Biotech Opportunities's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=571.858/( (766.121+1069.042)/ 2 )
=571.858/917.5815
=62.32 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

RTW Biotech Opportunities's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=288.47/( (766.121+1069.042)/ 2 )
=288.47/917.5815
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

RTW Biotech Opportunities Total Assets Related Terms

RTW Biotech Opportunities Total Assets Historical Data

* Premium members only.

The historical data trend for RTW Biotech Opportunities's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RTW Biotech Opportunities Total Assets Chart

RTW Biotech Opportunities Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 439.36 401.54 446.23 760.02 1,069.04

RTW Biotech Opportunities Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 446.23 0.00 760.02 766.12 1,069.04
LSE:RTW
36GF Score
RTW Biotech Opportunities Ltd LSE:RTW
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RTW Biotech Opportunities Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

RTW Biotech Opportunities's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=865.223+203.819
=1,069.0

RTW Biotech Opportunities's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=865.223+203.819
=1,069.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $1,069.0 Mil mean?
RTW Biotech Opportunities (LSE:RTW) has a Total Assets of $1,069.0 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on RTW Biotech Opportunities and its competitors.
Is RTW Biotech Opportunities' Total Assets too high?
RTW Biotech Opportunities' current Total Assets is $1,069.0 Mil. Overall, RTW Biotech Opportunities has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' Total Assets compare to BLK and BX?
RTW Biotech Opportunities' Total Assets of $1,069.0 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for an Asset Management company?
A good Total Assets depends on the Asset Management industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on RTW Biotech Opportunities and its competitors. RTW Biotech Opportunities's current Total Assets is $1,069.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current Total Assets of $1,069.0 Mil. The current Total Assets is $1,069.0 Mil. RTW Biotech Opportunities' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current Total Assets is $1,069.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RTW Biotech Opportunities Business Description

Address St Julian’s Avenue, 1st Floor, Royal Chambers, St Peter Port, GGY, GY1 3JX
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
36GF Score

Get the complete analysis for LSE:RTW

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.43
Price